Enjoy complimentary customisation on priority with our Enterprise License!
The Africa HIV treatment drugs market size is estimated to grow by USD 280.2 million at a CAGR of 3.2% between 2023 and 2028. Market growth is influenced by several critical factors, including the rising prevalence of sexually transmitted diseases (STDs), supportive international programs, and collaborative efforts with governments. The increasing incidence of STDs underscores the urgent need for diagnostic, treatment, and prevention solutions, driving demand within the healthcare sector. International programs aimed at STD prevention and management provide funding, expertise, and infrastructure support, facilitating market expansion globally. Collaborations with governments further enhance market growth by promoting public health initiatives, regulatory compliance, and funding for research and development. These factors collectively contribute to the expansion of the market by addressing healthcare challenges, improving access to STD healthcare services, and advancing medical technologies. As awareness grows and healthcare priorities align with global health agendas, the market for STD-related products and services is poised for growth, driven by comprehensive approaches to disease prevention and management on a global scale.
To learn more about this report, Download the FREE Report Sample
The market is influenced by a complex interplay of biological factors, social factors, behavioral factors, cultural factors, economic factors, and structural factors. Rising HIV infection rates and HIV transmission continue to drive demand for effective pharmaceutical solutions. Pharmaceutical companies face significant competition in pricing and vendor selection, necessitating thorough research reports and analysis by report analysts to inform strategic decisions. The profit margins in this market are impacted by rising investments in research and development to develop innovative therapies and improve treatment outcomes. Advancements in telemedicine and mobile health are enhancing vendor capabilities in reaching diverse patient populations, leveraging mobile phones for outreach and support. Promotions for HIV drugs often involve educational campaigns that address both medical and social aspects of HIV management. Both qualitative research and quantitative research play crucial roles in understanding patient needs and preferences, guiding the development of targeted therapies. As the market continues to evolve, the summation of data from various sources informs regulatory decisions and healthcare policies aimed at combating HIV effectively.
The increasing prevalence of STDs is notably driving the market. STDs are caused by the transmission of different bacteria, viruses, and parasites due to the exchange of bodily fluids during sexual intercourse. STDs can affect both men and women. There are more than 30 different bacteria, viruses, and parasites that can cause STDs. HIV/AIDS is one such type of STD. Sub-Saharan Africa ranks first in the annual incidence of STDs when compared to other regions.
The increasing incidence and prevalence of STDs are spurring the demand for the screening, diagnosis, and treatment of HIV at the earliest to reduce the chances of mortality. Companies present across Africa are focusing on offering a wide range of treatment drugs to affected people. Hence, the increasing incidence and prevalence of STDs in several places are expected to foster the growth of the market during the forecast period.
The awareness campaigns conducted by various organizations are major market trends. The prevalence of STDs, such as HIV/AIDS, has increased in Africa. Thus, governments of different countries are taking initiatives to increase awareness of and funding for the development of new drugs to treat STDs. For instance, African countries such as Botswana, Cote d'Ivoire, the Democratic Republic of the Congo, Eswatini, Malawi, Rwanda, South Africa, and Nigeria provide strategic support to the CDC's Division of HIV/AIDS Prevention and communicate with various partners and stakeholders about HIV prevention methods, policies, and programs.
Similarly, the UNAIDS program of the UN is making vigorous efforts to end HIV AIDS being a public threat by 2030. It helps governments, the private sector, and communities by providing direction, consultancy, planning and coordination, and technical support to promote life-saving HIV services. Thus, the growing involvement of various organizations to increase awareness about HIV is expected to increase the demand for HIV treatment drugs and, in turn, fuel the growth opportunity for the market during the forecast period.
The lack of diagnosis of HIV and access to modern medicines may impede the market. in Africa, there are still significant social and economic barriers that prevent people from being tested for HIV due to the fear of testing positive for HIV, which is seen as a stigma. Thus, some individuals are diagnosed with the disease for the first time only after they have been brought to the hospital following a seizure.
Caregivers are forced to either control seizures or treat the underlying HIV infection as the HIV infection has generally reached an advanced stage. Similarly, most African countries with high rates of HIV infection continue to rely largely on older antiepileptic drugs (AED) for seizure management, making HIV treatment less effective. Such factors may hinder the growth of the market during the forecast period.
Our analysis of the life cycle of the market indicates a movement from the innovator’s stage to the laggard’s stage. The market research and growth report illustrates the lifecycle of the market, focusing on the adoption rates of the major countries, including Uganda, Nigeria, and South Africa. Technavio's market forecasting report has included key purchase criteria, adoption rates, adoption lifecycles, and drivers of price sensitivity to help companies evaluate and develop strategies from 2022 to 2027.
Companies are implementing various strategies, such as strategic alliances, partnerships, mergers and acquisitions, geographical expansion, and product/service launches, to enhance their presence in the market
Our market growth and forecasting report includes detailed analyses of the market’s competitive landscape and offers information on 20 market companies, including :
Qualitative and quantitative analysis of Companies has been conducted to help clients understand the wider business environment as well as the strengths and weaknesses of key market players. Data is qualitatively analyzed to categorize Companies as pure play, category-focused, industry-focused, and diversified; it is quantitatively analyzed to categorize Companies as dominant, leading, strong, tentative, and weak.
The market share by the reverse transcriptase inhibitors segment will be significant during the forecast period. Reverse transcriptase inhibitors are pharmaceutical drugs used to treat and manage HIV. They belong to the anti-retroviral class of drugs. Reverse transcriptase inhibitors are further classified into two types, namely nucleoside reverse transcriptase inhibitors (NRTI) and non-nucleoside reverse transcriptase inhibitors (NNRTI). The large-scale availability of NRTIs and NNRTIs for HIV treatment is responsible for the favorable growth of this segment.
Get a glance at the market contribution of various segments Request a PDF Sample
The reverse transcriptase inhibitors segment showed a gradual increase in market share with USD 698.70 million in 2018. Some of the antiviral drugs used in anti-retroviral therapy include efavirenz, etravirine, and nevirapine, among others. Furthermore, the high use of NNRTI drugs among children and adults and growing R&D activities are expected to drive the growth of the reverse transcriptase inhibitors segment during the forecast period.
The market research report provides comprehensive data (region wise segment analysis), with forecasts and estimates in "USD Million" for the period 2024 to 2028, as well as historical data from 2018 to 2022 for the following segments.
You may also interested in below market reports:
HIV Drugs Market HIV Drugs Market by Distribution Channel, Therapy, and Geography - Forecast and Analysis
Immunotherapy Drugs Market Immunotherapy Drugs Market Analysis North America, Europe, Asia, Rest of World (ROW) - US, Germany, UK, China, Japan - Size and Forecast
Point of Care (POC) HIV Testing Market Point of Care (POC) HIV Testing Market Analysis North America, Europe, Asia, Rest of World (ROW) - US, Germany, France, UK, China - Size and Forecast
The market is characterized by continuous innovation and significant investments in healthcare infrastructure to address rising HIV cases globally. Pharmaceutical companies like GSK play a pivotal role in developing both HIV medications and generic versions to enhance treatment coverage, particularly in underserved areas and remote regions with limited healthcare access. The introduction of long-acting HIV therapies such as cabotegravir marks a shift towards improving medication adherence and reducing the burden of frequent dosing.
Technological advancements, including internet connectivity and telemedicine services, facilitate remote consultations and provide essential counseling services to patients in geographically distant locations, mitigating transportation costs and addressing healthcare workforce shortages. Challenges persist in ensuring supply chains reach clinics and retail pharmacies in rural areas, impacting health outcomes and treatment strategies. However, these challenges also present emerging opportunities for enhancing healthcare delivery and optimizing treatment strategies through collaborative efforts between public health initiatives and private sector innovations.
The Market in Africa faces unique challenges due to factors like geographical distance and limited healthcare infrastructure in remote areas. Despite these hurdles, there is rising awareness about HIV/AIDS treatment options, driving demand in both retail pharmacies and hospitals across the continent. The market encounters potential challenges in ensuring widespread access to medications and maintaining consistent supply chains. Efforts are underway to overcome logistical barriers, HIV drug and improve distribution networks to reach underserved populations effectively. As stakeholders collaborate to address these issues, advancements in treatment protocols and healthcare interventions are crucial for enhancing patient outcomes and combating the HIV epidemic in Africa.
Market Scope |
|
Report Coverage |
Details |
Page number |
162 |
Base year |
2023 |
Forecast period |
2024-2028 |
Growth momentum & CAGR |
Accelerate at a CAGR of 3.2% |
Market growth 2024-2028 |
USD 280.2 million |
Market structure |
Fragmented |
YoY growth 2023-2024(%) |
3.06 |
Competitive landscape |
Leading Companies, Market Positioning of Companies, Competitive Strategies, and Industry Risks |
Key companies profiled |
Abbott Laboratories, AbbVie Inc., Alpha Pharma, Aspen Pharmacare Holdings Ltd., AstraZeneca Plc, Aurobindo Pharma Ltd., Avacare Health, Boehringer Ingelheim International GmbH, Cipla Inc., F. Hoffmann La Roche Ltd., Gilead Sciences Inc., GlaxoSmithKline Plc, Hetero Labs Ltd., Johnson and Johnson Services Inc., Merck and Co. Inc., SSI Diagnostica AS, Sun Pharmaceutical Industries Ltd., Teva Pharmaceutical Industries Ltd., Theratechnologies Inc., and Viatris Inc. |
Market dynamics |
Parent market analysis, market growth analysis, market report, market forecast, Market growth inducers and obstacles, Fast-growing and slow-growing segment analysis, Market growth and Forecasting, COVID 19 impact and recovery analysis and future consumer dynamics, Market condition analysis for forecast period |
Customization purview |
If our report has not included the data that you are looking for, you can reach out to our analysts and get segments customized. |
We can help! Our analysts can customize this report to meet your requirements. Get in touch
1 Executive Summary
2 Market Landscape
3 Market Sizing
4 Historic Market Size
5 Five Forces Analysis
6 Market Segmentation by Drug Class
7 Market Segmentation by Route of Administration
8 Customer Landscape
9 Geographic Landscape
10 Drivers, Challenges, and Opportunity/Restraints
11 Competitive Landscape
12 Competitive Analysis
13 Appendix
Get lifetime access to our
Technavio Insights
Quick Report Overview:
Cookie Policy
The Site uses cookies to record users' preferences in relation to the functionality of accessibility. We, our Affiliates, and our Vendors may store and access cookies on a device, and process personal data including unique identifiers sent by a device, to personalise content, tailor, and report on advertising and to analyse our traffic. By clicking “I’m fine with this”, you are allowing the use of these cookies. Please refer to the help guide of your browser for further information on cookies, including how to disable them. Review our Privacy & Cookie Notice.